Jinxin Fertility Group Limited (JXR, 01951) disclosed a fresh on-market share repurchase of 1.41 million ordinary shares on 22 September 2026 at prices between HKD 2.125 and HKD 2.145, for a total consideration of HKD 3.00 million. The volume-weighted average cost was HKD 2.1338 per share.
Following the transaction, JXR’s issued share capital (excluding treasury shares) declined to 2.67587 billion shares, while treasury shares expanded to 29.18 million. Total issued shares remained unchanged at 2.70504 billion.
The repurchase forms part of the mandate approved on 25 June 2026, which authorises the company to buy back up to 262.51 million shares. Cumulative purchases under this mandate have reached 41.72 million shares, representing 1.59 % of the company’s issued share capital on the mandate date. Approximately 220.79 million shares remain available for repurchase.
In addition, 32 tranches executed between 27 March and 25 August 2026, aggregating 92.47 million shares (about 3.45 % of the 21 September 2026 share base), are earmarked for cancellation but had not yet been cancelled as of 22 September 2026. Prices paid for these earlier repurchases ranged from HKD 1.9687 to HKD 2.4653 per share.
Under Hong Kong Stock Exchange rules, JXR is subject to a 30-day moratorium on issuing new shares or selling treasury shares, lasting until 22 October 2026.
Comments